A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia

Inclusion Criteria:

- Relapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion
of investigator

- Eastern Cooperative Oncology Group (ECOG) <= 1

- Adequate bone marrow independent of growth factor support, renal and hepatic function
per defined laboratory criteria

Exclusion Criteria:

- History or clinically suspicious for cancer-related Central Nervous System disease

- Receipt of allogenic or autologous stem cell transplant

- Recent history (within 1 year of first dose) of underlying, predisposing condition of
bleeding or currently exhibits signs of bleeding

- Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis

- Active immune thrombocytopenic purpura or history of being refractory to platelet
transfusions (within 1 year of first dose)